Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance

References

• Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metabolism and Disposition 2005; 33: 419–425
   PubMed Web of Science ®Google Scholar
• Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Current Drug Metabolism 2007; 8: 33–45
   PubMed Web of Science ®Google Scholar
• Blanchard N, Alexandre E, Abadie C, Lave T, Heyd B, Mantion G, Jaeck D, Richert L, Coassolo P. Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 2005; 35: 1–15
   PubMed Web of Science ®Google Scholar
• Blanchard N, Hewitt NJ, Silber P, Jones H, Coassolo P, Lave T. Prediction of hepatic clearance using cryopreserved human hepatocytes: A comparison of serum and serum-free incubations. Journal of Pharmacy and Pharmacology 2006; 58: 633–641
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 1980; 8: 165–176
   PubMedGoogle Scholar
• Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metabolism and Disposition 2007; 35: 293–301
   PubMed Web of Science ®Google Scholar
• Ekins S, Obach RS. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics 2000; 295: 463–473
   PubMed Web of Science ®Google Scholar
• Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition 2000; 28: 560–566
   PubMed Web of Science ®Google Scholar
• Foti RS, Fisher MB. Impact of incubation conditions on bufuralol human clearance predictions: Enzyme lability and nonspecific binding. Drug Metabolism and Disposition 2004; 32: 295–304
   PubMed Web of Science ®Google Scholar
• Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharmaceutical Research 2006; 23: 533–539
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement. Drug Metabolism and Disposition 2006; 34: 724–726
   PubMed Web of Science ®Google Scholar
• Hallifax D, Rawden HC, Hakooz N, Houston JB. Prediction of metabolic clearance using cryopreserved human hepatocytes: Kinetic characteristics for five benzodiazepines. Drug Metabolism and Disposition 2005; 33: 1852–1858
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechon MJG, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews 2007; 39: 159–234
   PubMed Web of Science ®Google Scholar
• Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 1994; 47: 1469–1479
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research 2004; 21: 785–792
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data Using physiologically based and empirical approaches. Pharmaceutical Research 2005; 22: 103–112
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacology and Therapeutics 1997; 73: 147–171
   PubMed Web of Science ®Google Scholar
• Jouin D, Blanchard N, Alexandre E, Delobel F, David-Pierson P, Lave T, Jaeck D, Richert L, Coassolo P. Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. European Journal of Pharmaceutics and Biopharmaceutics 2006; 63: 347–355
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metabolism and Disposition 2002; 30: 694–700
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: Correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data 2008, Drug Metabolism and Disposition fast forward: dmd.108.020834v1
   Google Scholar
• Lau YY, Sapidou E, Cui X, White RE, Cheng KC. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metabolism and Disposition 2002; 30: 1446–1454
   PubMed Web of Science ®Google Scholar
• Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharmaceutical Research 1997; 14: 152–155
   PubMed Web of Science ®Google Scholar
• Li AP. Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chemico-biological Interactions 2007; 168: 16–29
   PubMed Web of Science ®Google Scholar
• Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug Metabolism and Disposition 2006; 34: 1600–1605
   PubMed Web of Science ®Google Scholar
• Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metabolism and Disposition 2003; 31: 606–611
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metabolism and Disposition 2004; 32: 1247–1253
   PubMed Web of Science ®Google Scholar
• McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. British Journal of Clinical Pharmacology 2000; 49: 453–461
   PubMed Web of Science ®Google Scholar
• Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochemical Pharmacology 2006; 71: 1531–1539
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 46–58
   PubMed Web of Science ®Google Scholar
• Reddy A, Heimbach T, Freiwald S, Smith D, Winters R, Michael S, Surendran N, Cai H. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 319–326
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 2005; 33: 1304–1311
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9: 503–512
   PubMedGoogle Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences 2006; 27: 425–446
   PubMed Web of Science ®Google Scholar
• Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. Journal of Pharmacology and Experimental Therapeutics 2002; 301: 382–390
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. Chemico-biological Interactions 2007; 168: 2–15
   PubMed Web of Science ®Google Scholar
• Tang C, Hochman JH, Ma B, Subramanian R, Vyas KP. Acyl glucuronidation and glucosidation of a new and selective endothelin ET(A) receptor antagonist in human liver microsomes. Drug Metabolism and Disposition 2003; 31: 37–45
   PubMed Web of Science ®Google Scholar